AAPP 2024 industry supported symposia are scientific programs developed for educational purposes. All symposia at AAPP 2024 are designed for the psychiatric pharmacist and are included in participant registration fees. All symposia are in compliance with Accreditation Council for Pharmacy Education (ACPE) criteria for planning and implementation, and each one provides 1.5 contact hours of ACPE credit.
Attendees! A few reminders:
Lunch will be served from 11:15-11:30 AM Eastern in National A, immediately before the program.
Overview: Modulation of dopamine levels in key brain areas affected in schizophrenia has historically been achieved by using dopamine D2 receptor antagonists. Although such D2 receptor blockade may ameliorate positive symptoms of schizophrenia, it often comes at the cost of high motor side effect risk and lack of efficacy for treating the non-positive symptoms of schizophrenia. In this presentation, the speaker will bring to light the intricate neurocircuitry affecting dopaminergic neurotransmission as it relates to schizophrenia. With this understanding, potential utilization of novel agents to modulate dopamine levels without directly affecting dopamine D2 receptors will be discussed and evaluated.
Learning Objectives
Faculty
|
Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University; Syracuse, NY Chief Medical Officer, Neuroscience Education Institute; Carlsbad, CA |
Supported by
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Lunch will be served from 11:15-11:30 AM Eastern in National A, immediately before the program.
Overview: Although categorical classifications may be useful for clinical practice, most of the evidence points to a dimensional (spectrum) view of mood disorders. Depression with co-occurring hypomania (DMX) is much more common than clinicians realize, leading to underdiagnosis and a paucity of appropriate treatment for patients with mixed features. This talk will provide healthcare providers with a detailed look at mixed features across the lifespan, including ways to identify mixed features early and strategies to treat it effectively.
Learning Objectives
Faculty
|
Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University; Syracuse, NY Chief Medical Officer, Neuroscience Education Institute; Carlsbad, CA |
Supported by
This activity is supported by an educational grant from Intra-Cellular Therapies, Inc.
Lunch will be served from 11:15-11:30 AM Eastern in National A, immediately before the program.
Overview: In this, the digital age, where more and more individuals rely heavily on their electronic devices for managing many aspects of day-to-day living, digital apps aimed at improving mental health are becoming increasingly common and have been shown to be effective. This presentation will discuss the efficacy of available and emerging prescription digital therapeutics (PDTs) in treating a variety of mental health concerns including sleep, schizophrenia, ADHD, and substance use disorders as well as practical tips for successfully incorporating PDTs into individualized treatment strategies for patients.
Learning Objectives
Faculty
|
Kari Franson, PharmD, PhD, BCPP Professor of Clinical Pharmacy, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences; Los Angeles, CA |
Supported by
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
